From: Modulation of doxorubicin cytotoxicity by resveratrol in a human breast cancer cell line
Treatment | IC50 (μg/ml) |
---|---|
DOX | 0.417 ± 0.107 |
DOX + RSVL (15 μg/ml) (supplied simultaneously) | 0.056a ± 0.026 |
DOX + RSVL (15 μg/ml) (RSVL supplied 24 h before DOX) | 0.035a,b ± 0.016 |